Low-level copy number changes of MYC genes have a prognostic impact in medulloblastoma
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- amplifikace genu * MeSH
- dítě MeSH
- genová dávka * MeSH
- hybridizace in situ fluorescenční MeSH
- interfáze MeSH
- jaderné proteiny genetika MeSH
- kohortové studie MeSH
- lidé MeSH
- meduloblastom genetika MeSH
- míra přežití MeSH
- mladiství MeSH
- nádory mozečku genetika MeSH
- onkogenní proteiny genetika MeSH
- předškolní dítě MeSH
- prognóza MeSH
- prospektivní studie MeSH
- protoonkogen n-myc MeSH
- protoonkogenní proteiny c-myc genetika MeSH
- retrospektivní studie MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- jaderné proteiny MeSH
- MYC protein, human MeSH Prohlížeč
- MYCN protein, human MeSH Prohlížeč
- onkogenní proteiny MeSH
- protoonkogen n-myc MeSH
- protoonkogenní proteiny c-myc MeSH
High-level amplifications of MYC genes are associated with poor outcomes in childhood medulloblastoma (MB). However, the occurrence of MYCN and MYCC copy number increases below the intense amplification pattern is rarely reported, and its clinical impact has not yet been determined. Here, we describe this phenomenon and its prognostic significance in a cohort of 29 MB patients. Using interphase fluorescence in situ hybridization (I-FISH), low-level copy number alterations, i.e. gain of MYCN, were shown in 5/27 (19%) samples, whereas amplification was revealed in only 1/27 (4%) samples. MYCC gain was revealed in 6/29 (21%) MB, while amplification was disclosed in only 2/29 (7%). Hyperploidy and co-incidence of gains in both MYC loci were frequently observed in samples with copy number aberrations. Survival analysis has clearly shown that MYC copy number increases are associated with lowered event-free survival and overall survival in MB. In the case of MYCN, this negative correlation was statistically significant. We conclude that limited numerical alterations in loci 2p24 (MYCN) and 8q24 (MYCC), as assessed by I-FISH, are present in MB with a higher frequency than high-level amplifications. Poor prognoses were observed in patients with copy number increases in MYC genes. Our data illustrate the importance of further investigations in multicenter trials to better refine the emerging genomic-based prognostic stratification in MB.
Zobrazit více v PubMed
J Neurooncol. 2010 Apr;97(2):247-55 PubMed
Int J Cancer. 2000 Sep 20;89(5):395-402 PubMed
J Neuropathol Exp Neurol. 2000 Oct;59(10):857-65 PubMed
J Neurosurg Pediatr. 2009 Jan;3(1):61-5 PubMed
J Neurooncol. 2009 Nov;95(2):271-279 PubMed
Mayo Clin Proc. 1994 Apr;69(4):359-65 PubMed
Cancer Metastasis Rev. 1991 Dec;10(4):289-99 PubMed
Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1358-63 PubMed
J Clin Lab Anal. 2008;22(2):123-30 PubMed
Cancer Res. 2004 May 1;64(9):3103-11 PubMed
Neuropathol Appl Neurobiol. 2005 Aug;31(4):422-8 PubMed
Tumori. 1991 Apr 30;77(2):118-21 PubMed
Bone Marrow Transplant. 2005 Dec;36(11):939-45 PubMed
J Pathol. 2009 May;218(1):86-94 PubMed
J Clin Oncol. 1998 Jul;16(7):2478-85 PubMed
Cancer. 2002 Jan 15;94(2):552-60 PubMed
Am J Pathol. 1988 Mar;130(3):472-84 PubMed
Pathology. 1999 Nov;31(4):337-44 PubMed
J Neurooncol. 1987;4(3):287-91 PubMed
Lancet Oncol. 2006 Oct;7(10):813-20 PubMed
Clin Cancer Res. 2004 Aug 15;10(16):5482-93 PubMed
J Pediatr Hematol Oncol. 1998 Jan-Feb;20(1):18-25 PubMed
Neoplasma. 2007;54(3):212-8 PubMed
J Neuropathol Exp Neurol. 2003 Jun;62(6):627-32 PubMed
Br J Cancer. 1989 Jun;59(6):889-94 PubMed
Clin Cancer Res. 2001 Aug;7(8):2425-33 PubMed
J Clin Oncol. 2005 Nov 1;23(31):7951-7 PubMed
N Engl J Med. 2005 Mar 10;352(10):978-86 PubMed
Cancer Res. 2009 Dec 1;69(23):8839-43 PubMed
Br J Cancer. 2009 May 5;100(9):1471-82 PubMed
Arch Pathol Lab Med. 2002 May;126(5):540-4 PubMed
Brain Pathol. 2007 Apr;17(2):151-64 PubMed
Eur J Cancer. 2009 Jun;45(9):1700-8 PubMed
Apoptosis. 2009 Apr;14(4):424-38 PubMed
Cell Cycle. 2006 Nov;5(22):2666-70 PubMed
Clin Cancer Res. 2007 May 1;13(9):2651-7 PubMed
Brain Pathol. 2002 Jan;12(1):36-44 PubMed
J Clin Oncol. 2009 Apr 1;27(10):1627-36 PubMed
Cancer Res. 2006 Jan 15;66(2):673-81 PubMed
Pediatr Surg Int. 2008 Oct;24(10):1095-100 PubMed
J Clin Oncol. 1993 Apr;11(4):616-22 PubMed
Folia Biol (Praha). 2000;46(5):187-90 PubMed
Br J Neurosurg. 2009 Aug;23(4):364-75 PubMed
Eur J Cancer. 2006 Nov;42(17):2996-3003 PubMed
Arch Neurol. 2008 Nov;65(11):1419-24 PubMed
J Neurooncol. 2009 Oct;95(1):81-85 PubMed
Lancet Neurol. 2007 Dec;6(12):1073-85 PubMed
J Clin Oncol. 2000 Mar;18(5):1027-35 PubMed
Clin Neurol Neurosurg. 2000 Dec;102(4):203-209 PubMed
J Clin Oncol. 2006 Sep 1;24(25):4202-8 PubMed
J Neuropathol Exp Neurol. 2004 May;63(5):441-9 PubMed
